PUQE-N: Pregnancy Specific Nausea Questionnaire (PUQE) Translated and Tested in Norwegian

Sponsor
Haukeland University Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT01836835
Collaborator
(none)
69
2
20
34.5
1.7

Study Details

Study Description

Brief Summary

Nausea in early pregnancy (emesis gravidarum) is very common but most often self-limiting. Hyperemesis gravidarum; where nausea and vomiting is severe and protracted is potentially dangerous for the woman and her foetus and necessitates hospital treatment. An English questionnaire (PUQE; Pregnancy Unique Questionnaire of Emesis) exists that can differentiate between uncomplicated emesis and the severe hyperemesis condition. This questionnaire has been translated to Norwegian. The investigators want to test the ability of this questionnaire to differentiate the grade of nausea/vomiting between a group of presumed normal pregnant woman and patients treated for hyperemesis gravidarum in a Norwegian population. The investigators also want to relate the PUQE questionnaire scoring to the women/patients' self-reported nutritional intake during 24 hours.

Condition or Disease Intervention/Treatment Phase
  • Other: Pregnancy Unique Questionnaire of Emesis (PUQE)
  • Other: 24 hours self-reported nutritional intake form

Detailed Description

This is a prospective case-control study validating Pregnancy Unique Questionnaire of Emesis (PUQE) in a Norwegian population. The questionnaire has been translated from English to Norwegian by authorized translators. The Norwegian questionnaire's title is Svangerskaps Utløst Kvalme Kvantifisering (SUKK). The Norwegian version has been independently back-translated to English. The back-translated version has been approved by the original author Gideon Koren.

The primary objective is to evaluate if the questionnaire score is significantly different between a group of presumed healthy pregnant woman and a group of patients hospitalized with hyperemesis gravidarum.

The women will also fill in a self-reported 24-hours nutritional intake diary and this will be related to the Pregnancy Unique Questionnaire of Emesis (PUQE)score. For patients hospitalized with hyperemesis gravidarum the Pregnancy Unique Questionnaire of Emesis (PUQE)score both at admission and discharge will be compared.

Background clinical information for both groups at enrollment will be recorded as well as pregnancy outcome for woman and child.

The study has been approved by the Institutional Board as well as the Norwegian Regional Ethical Committee (REK Norway). Women will be included after giving informed written consent. Data will be stored electronically, anonymised, at a designated research server in accordance with the institutional research rules.

The sample size have been determined on basis of a similar study evaluating different nutritional status in emesis and hyperemesis patients, using 20 patients in each group. We aim to include 30 patients in each group.

Patients with diagnose of Hyperemesis gravidarum admitted form 1st of May 2013 will be consecutively asked to participate. Control patients will be recruited by invitation at primary care facilities or private out-patient gynaecologists.

Statistical analyses will be performed using Statistical Package for the Social Sciences (SPSS). Categorical variables will be compared using Chi-square test and continuous variables by non-parametric tests. Paired test will be used when comparing Pregnancy Unique Questionnaire of Emesis (PUQE)scores sequentially from admittance to discharge.

Study Design

Study Type:
Observational [Patient Registry]
Actual Enrollment :
69 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Case-cohort Validation Study of Pregnancy Unique Questionnaire of Emesis (PUQE) in Norwegian
Study Start Date :
May 1, 2013
Actual Primary Completion Date :
Apr 1, 2014
Actual Study Completion Date :
Jan 1, 2015

Arms and Interventions

Arm Intervention/Treatment
Hyperemesis gravidarum

Women diagnosed with hyperemesis gravidarum admitted to hospital Pregnancy Unique Questionnaire of Emesis (PUQE) and 24 hours self-reported nutritional intake form administered

Other: Pregnancy Unique Questionnaire of Emesis (PUQE)
For hyperemesis gravidarum patients the Pregnancy Unique Questionnaire of Emesis (PUQE) (3 questions regarding the amount of nausea and vomiting during 24 hours) will be answered both at hospital admittance and discharge. For control patients the questionnaire will be answered at inclusion.

Other: 24 hours self-reported nutritional intake form
A nutritional intake form where relevant food and liquid items can be checked prospectively after consummation during 24 hours. This form will be filled in starting the morning following inclusion.

Healthy pregnant women

Women with presumed normal pregnancy Pregnancy Unique Questionnaire of Emesis (PUQE) and 24 hours self-reported nutritional intake form administered

Other: Pregnancy Unique Questionnaire of Emesis (PUQE)
For hyperemesis gravidarum patients the Pregnancy Unique Questionnaire of Emesis (PUQE) (3 questions regarding the amount of nausea and vomiting during 24 hours) will be answered both at hospital admittance and discharge. For control patients the questionnaire will be answered at inclusion.

Other: 24 hours self-reported nutritional intake form
A nutritional intake form where relevant food and liquid items can be checked prospectively after consummation during 24 hours. This form will be filled in starting the morning following inclusion.

Outcome Measures

Primary Outcome Measures

  1. Pregnancy Unique Questionnaire of Emesis (PUQE) score reported by hyperemesis patients versus normal pregnant women [24 hours after inclusion]

    Pregnancy Unique Questionnaire of Emesis (PUQE) score range from 3 to 15. Scores reported for the first 24 hours after inclusion will be compared between hyperemesis patients and healthy pregnant control women

Secondary Outcome Measures

  1. Pregnancy Unique Questionnaire of Emesis (PUQE) score in relation to self reported 24 hours nutritional intake registration (estimated caloric intake)in hyperemesis patients versus normal pregnant women [24 hours after inclusion]

    The Pregnancy Unique Questionnaire of Emesis (PUQE) scores from hyperemesis and control women will be compared to self-reported 24 hours nutritional intake

Other Outcome Measures

  1. Change in Pregnancy Unique Questionnaire of Emesis (PUQE) score from hospital admittance to discharge [From hospital admission to discharge, mean 7 days]

    Change in Pregnancy Unique Questionnaire of Emesis (PUQE) score for hyperemesis gravidarum patients from first assessment at hospital admission and again at hospital discharge

  2. Pregnancy Unique Questionnaire of Emesis (PUQE) score at inclusion related to change in patient weight (kg)from start of pregnancy to inclusion for hyperemesis patients versus normal pregnant women [From pre-pregnancy to inclusion (mean 9 weeks pregnancy length)]

    Change of weight (gain or loss) from pre-pregnant to time of inclusion related to Pregnancy Unique Questionnaire of Emesis (PUQE) scores for hyperemesis and control women

  3. Change of Pregnancy Unique Questionnaire of Emesis (PUQE) score and patient weight (kg) [From inclusion to delivery (mean 7 months)]

    Change of weight (gain or loss) from inclusion to time of delivery related to Pregnancy Unique Questionnaire of Emesis (PUQE) scores at inclusion for hyperemesis and control women

  4. Pregnancy Unique Questionnaire of Emesis (PUQE) score related to the baby's weight (kg)in hyperemesis patients versus normal pregnant women [From inclusion to delivery (mean 7 months)]

    Pregnancy Unique Questionnaire of Emesis (PUQE) scores at inclusion for hyperemesis versus control women is related to the baby's weight at delivery

Eligibility Criteria

Criteria

Ages Eligible for Study:
16 Years to 50 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Pregnant healthy women (controls)

  • Patients admitted to hospital for hyperemesis gravidarum

Exclusion Criteria:
  • Pregnancy duration at inclusion more than 16 weeks

  • Unable to understand and read/write Norwegian

  • Conditions other than hyperemesis leading to nausea/vomiting

Contacts and Locations

Locations

Site City State Country Postal Code
1 Dpt. of Obstetrics and Gynaecology, Haukeland University Hospital Bergen Hordaland Norway 5021
2 Dpt Obstetrics Gynaecology, Stavanger University Hospital Stavanger Rogaland Norway 4000

Sponsors and Collaborators

  • Haukeland University Hospital

Investigators

  • Principal Investigator: Jone Trovik, MD, PhD, Haukeland University Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Haukeland University Hospital
ClinicalTrials.gov Identifier:
NCT01836835
Other Study ID Numbers:
  • 2013/465
First Posted:
Apr 22, 2013
Last Update Posted:
Mar 30, 2015
Last Verified:
Mar 1, 2015
Keywords provided by Haukeland University Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 30, 2015